Active ingredientMoexipril HClCat. No. P-M156-001CAS 82586-52-5Family · Pharmaceutical analytical standards
Moexipril
An ACE inhibitor for high blood pressure, patented in 1980 and approved in 1995: it is a prodrug that the liver converts into the active form, moexiprilat. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?Besides blocking the ACE enzyme, it has also shown an inhibitory effect on phosphodiesterase 4 (PDE4), an enzyme from an entirely different family.
Go to the active ingredient →Active ingredientMoexipril HClCat. No. P-M156-001CAS 82586-52-5
Pharmacopoeial impurityMoexipril USP Related Compound ACat. No. P-M156-002CAS 103775-14-0
Pharmacopoeial impurityMoexipril USP Related Compound C MaleateCat. No. P-M156-003CAS 103733-40-0
MetaboliteMoexipril Acyl GlucuronideCat. No. P-M156-004CAS 1260613-88-4
Isotopically labelledMoexipril-d5Cat. No. P-M156-005CAS 1356929-49-1
Isotopically labelledMoexipril-d5 HClCat. No. P-M156-006
NitrosamineN-Nitroso MoexiprilCat. No. P-M156-007CAS 1026879-47-9
ImpurityDiketopiperazine moexiprilatCat. No. P-M156-008CAS 112468-23-2No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.